12:00 AM
May 27, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Resminostat: Phase I/II started

Yakult Honsha began a Japanese Phase I/II trial of resminostat plus sorafenib in up to 164 patients. The dose-escalation Phase I portion will determine the MTD and potential dose-limiting toxicities (DLTs). The Phase II portion will compare up to 600...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >